SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert S. who wrote (7547)10/27/1998 10:01:00 AM
From: aknahow  Respond to of 17367
 
Robert S, thanks for the, additional, narrow window thought. This poses a real dilemma for me. You have a real point on the common symptoms. After reading your post, I wonder at times, if I too also might have meningococcemia. So do I continue to give credence to Dr. Giroir? Must ponder this for a long time. O.K., I reached a conclusion.



To: Robert S. who wrote (7547)10/27/1998 12:56:00 PM
From: LarryS  Respond to of 17367
 
The first patient with mening will probably not get BPI but
once the medical community knows there is a problem
in their area, I bet BPI will be one of the first items prescribed?
If it is not given to patients, once an outbreak is detected, then it would open the medical practitioner to legal liability....and who wants that? We might miss the first patient but not the later ones.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News